Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: GBP5

Summary for GBP5

Gene information	Gene symbol	GBP5
	Ensembl ID	ENSG00000154451
	Entrez ID	115362
	Gene name	guanylate binding protein 5
	Synonyms	NA
	Gene type	protein_coding
	UniProtAcc	Q96PP8

Top

Dataset with differentially expressed gene: GBP5

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.417223	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.360689	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.488646	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	-0.46692	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.517894	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.495159	1.83e-39
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.380148	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.561424	6.33e-23
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.305498	6.74e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.674878	2.40e-10
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	0.252303	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	0.284288	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	0.309742	3.07e-31
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.348992	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.741301	2.00e-09
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.704658	2.14e-10
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.891367	1.22e-13
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.304691	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.500152	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.349056	1.19e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.313997	5.03e-07

Top

Expression of GBP5 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to GBP5

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating GBP5

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
GBP5	hsa-miR-335-3p	95.408	NM_052942
GBP5	hsa-miR-584-5p	94.3902	NM_052942
GBP5	hsa-miR-561-3p	94.1673	NM_052942
GBP5	hsa-miR-4789-3p	94.0777	NM_052942
GBP5	hsa-miR-4509	92.1404	NM_052942
GBP5	hsa-miR-340-5p	91.7495	NM_052942
GBP5	hsa-miR-96-5p	91.7411	NM_052942
GBP5	hsa-miR-5190	91.7093	NM_052942
GBP5	hsa-miR-12133	90.6806	NM_052942
GBP5	hsa-miR-1271-5p	90.6806	NM_052942
GBP5	hsa-miR-216b-5p	89.0901	NM_052942
GBP5	hsa-miR-527	87.5058	NM_052942
GBP5	hsa-miR-518a-5p	87.5058	NM_052942
GBP5	hsa-miR-4504	85.0472	NM_052942
GBP5	hsa-miR-29b-1-5p	84.2726	NM_052942
GBP5	hsa-miR-466	83.8482	NM_052942
GBP5	hsa-miR-142-5p	82.8326	NM_052942
GBP5	hsa-miR-5590-3p	82.8326	NM_052942
GBP5	hsa-miR-3156-5p	82.4507	NM_052942
GBP5	hsa-miR-4666a-3p	82.0728	NM_052942
GBP5	hsa-miR-618	80.3934	NM_052942

Page: 1

Top

Motifs and transcription factors (TFs) regulating GBP5

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
GBP5	transfac_pro__M06263	ZNF211 (directAnnotation).
GBP5	metacluster_141.2	E2F2; E2F3 (directAnnotation).
GBP5	swissregulon__mm__Elf3	ELF3 (inferredBy_Orthology).
GBP5	transfac_pro__M05613	ZNF35 (directAnnotation).
GBP5	transfac_pro__M05453	ZBTB26 (directAnnotation).
GBP5	transfac_pro__M06013	ZFP69B (directAnnotation).
GBP5	transfac_pro__M06153	ZNF83 (directAnnotation).
GBP5	transfac_pro__M01239	RELA (directAnnotation).
GBP5	tfdimers__MD00143	IKZF1; MZF1 (directAnnotation).
GBP5	metacluster_148.1	ATF2; ATF2; ATF3; ATF3; ATF3; ATF3; ATF4; ATF4; ATF6; ATF6; ATF6B; ATF7; BATF3; BATF3; CREB1; CREB1; CREB1; CREB3; CREB3; CREB5; CREB5; CREB5; CREM; CREM; FOS; FOS; FOSB; FOSB; FOSB; FOSL1; JDP2; JDP2; JUN; JUN; JUN; JUNB; JUND; MAF; MAF; MAFA; MAFA; MAFF; MAFF; MAFF; MAFF; MAFG; MAFG; ZBTB21 (directAnnotation). ATF1; ATF1; ATF1; ATF1; ATF6; ATF6; ATF6; ATF6; ATF6B; ATF6B; ATF6B; ATF6B; CREB1; CREB1; CREB3; CREB3; CREB3; CREB3; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L2; CREB3L2; CREB3L2; CREB3L2; CREB3L3; CREB3L3; CREB3L3; CREB3L3; CREB3L4; CREB3L4; CREB3L4; CREB3L4; CREM; CREM; CREM; CREM; JDP2; JUN; JUNB; JUND; MAFB (inferredBy_Orthology).
GBP5	metacluster_180.3	ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF4; ATF4; ATF6; ATF6B; ATF7; ATF7; BACH2; BATF3; BATF3; CREB1; CREB1; CREB3; FOSL1; FOSL2; JDP2; JUN; JUN; JUN; JUND; JUND; XBP1; ZBTB21 (directAnnotation). JDP2; JDP2; JUND (inferredBy_Orthology).
GBP5	transfac_pro__M04746	E2F1 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."